Expert Interview
Discussing the standard of care and the potential of Boehringer Ingelheim's BI 456906, a novel glucagon/GLP-1 receptor dual agonist, once-weekly injectable to treat obesity.
Ticker(s): ZEAL, Boehringer IngelheimInstitution: Optum
- Board Certified in Endocrinology, Diabetes & Metabolism and
Internal Medicine. - specializes in all disorders of the Endocrine system with a special interestin diabetes and thyroid disorders
- performs ultrasound guided fine needle aspirations of the thyroid.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
